The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | Increasing treatment options for NSCLC
David Gandara, MD from the University of California, Davis, CA discusses the recent change in the treatment landscape of advanced non-small cell lung cancer (NSCLC) and what we can expect in the future. There have been great advances in the treatment of advanced NSCLC, however an increase in the number of treatment options brings rise to new challenges and questions that need to be dealt with. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.
